Filtered By:
Cancer: Adenocarcinoma
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 29896 results found since Jan 2013.
Hemophagocytic lymphohistiocytosis due to pembrolizumab therapy for adenocarcinoma of the lung
Proc (Bayl Univ Med Cent). 2021 Jul 14;34(6):729-730. doi: 10.1080/08998280.2021.1945353. eCollection 2021.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a rare disorder of dysregulated inflammation. It is most commonly seen in children who have a predisposing genetic mutation. However, adults can contract an acquired version of the disorder secondary to an infectious, neoplastic, or other inflammatory insult. There have been several documented cases of HLH being induced by treatment with immunotherapy. Here, we present the case of a 71-year-old man who was receiving pembrolizumab for lung adenocarcinoma when he devel...
Source: Baylor University Medical Center Proceedings - November 4, 2021 Category: Universities & Medical Training Authors: James J Doyle James A Hall Kelsey Reely Jyothi Dodlapati Source Type: research
Synchronous development of prostate sarcoma and squamous cell carcinoma following radiotherapy
We present the case of a 78-year-old patient with a remote history of prostate adenocarcinoma, status post brachytherapy, who subsequently developed both prostate sarcoma and prostate squamous cell carcinoma secondary to the prior treatment. Because his cancer was metastatic, he was not a candidate for surgery and was treated with chemotherapy and palliative radiation.PMID:35261467 | PMC:PMC8865295 | DOI:10.1080/08998280.2021.1994909
Source: Baylor University Medical Center Proceedings - March 9, 2022 Category: Universities & Medical Training Authors: Vihitha Thota Keerthy Joseph Sudheer Konduru Manaswitha Thota Eugene J Choi Source Type: research
